Genmark Diagnostics, Inc. (GNMK): Ingo Chakravarty , SVP, International of Genmark Diagnostics, Inc. sold 582 shares on May 9, 2016. The Insider selling transaction was reported by the company on May 11, 2016 to the Securities and Exchange Commission. The shares were sold at $5.42 per share for a total value of $3,154.44 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 4, 2016, Michael Gleeson (SVP, North American Com. Ops.) sold 396 shares at $5.79 per share price.On May 4, 2016, Jon Faiz Kayyem (SVP, Research & Development) sold 135 shares at $5.79 per share price.Also, On May 4, 2016, Jennifer Anne Williams (SVP, Human Resources) sold 331 shares at $5.79 per share price.On May 4, 2016, Ingo Chakravarty (SVP, International) sold 396 shares at $5.79 per share price.
GenMark Diagnostics Inc: On Tuesday, May 10, 2016 heightened volatility was witnessed in GenMark Diagnostics Inc which led to swings in the share price. The shares opened for trading at $5.55 and hit $5.64 on the upside , eventually ending the session at $5.53, with a gain of 0.55% or 0.03 points. The heightened volatility saw the trading volume jump to 1,71,666 shares. The 52-week high of the share price is $10.84 and the company has a market cap of $237 M . The 52-week low of the share price is at $4.2.
Company has been under the radar of several Street Analysts.GenMark Diagnostics Inc is Reiterated by Needham to Buy while Lowering the Price Target of the company shares to $ 11 from a previous price target of $13 . The Rating was issued on Feb 24, 2016.
GenMark Diagnostics Inc. (GenMark) is a molecular diagnostics company. The Company is focused on developing and commercializing its eSensor detection technology. The Company’s electrochemical technology enables detection of multiple distinct biomarkers in a single sample. The Company’s XT-8 system received 510(k) clearance from the United States Food and Drug Administration (FDA) and is designed to support a range of molecular research and diagnostic tests with a workstation and disposable test cartridges. Its XT-8 system supports up to 24 independent test cartridges each of which can be run independently resulting in a workflow for its focused customers which are primarily hospitals and reference laboratories. It has an installed base of approximately 540 XT-8 analyzers or placements with its customers.